Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy in Advanced Ovarian Cancer
NCT00006453Phase 3Completed
- Sponsor
- AGO Study Group
- Start
- Sep 1999
- Primary completion
- Oct 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in ovarian cancer (2 arms), sponsored by AGO Study Group. Primary endpoint: Time to Progression up to 2 years. Started Sep 1999; status: completed.
02
Drugs
gemcitabine
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00006453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00006453.